Clinical Research Directory
Browse clinical research sites, groups, and studies.
177Lu-JH04 in Patients with FAP-Positive Tumors
Sponsor: First Affiliated Hospital of Fujian Medical University
Summary
This is a pilot study to assess the dosimetry, toxicity and response of 177Lu-JH04, a new FAP-targeted radiopharmaceutical, in patients with FAP-Positive Tumors. All patients underwent 68Ga-FAPI PET/CT for selection and were successively divided into three groups of 3 people each.The three groups received successively an approximately 3.70 GBq (100 mCi), 5.55 GBq (150 mCi) and 7.40 GBq (200 mCi) of 177Lu-JH04 up to 4 cycles.
Official title: Safety, Dosimetry and Treatment Response of 177Lu-JH04 in Patients with FAP-Positive Tumors
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
9
Start Date
2024-08-21
Completion Date
2025-08-31
Last Updated
2024-10-10
Healthy Volunteers
No
Interventions
3.70 GBq (100 mCi) of 177Lu-JH04
All 3 patients were intravenous injected with single dose 3.70 GBq (100 mCi) of 177Lu-JH04.
5.55 GBq (150 mCi) of 177Lu-JH04
All 3 patients were intravenous injected with single 5.55 GBq (150 mCi) of 177Lu-JH04
7.40 GBq (200 mCi) of 177Lu-JH04
All 3 patients were intravenous injected with single 7.40 GBq (200 mCi) of 177Lu-JH04
Locations (1)
Department of Nuclear Medicine, First Affiliated Hospital of Fujian Medical University
Fuzhou, Fujian, China